SciClone Pharmaceuticals (Holdings) Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SciClone Pharmaceuticals (Holdings) Limited
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.
The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- NovaMed Pharmaceuticals Inc.
- SciClone Pharmaceuticals Inc.